Addyi Monitoring Schedule: Labs & Exams

How Flibanserin Works: Mechanism Behind the Monitoring

Flibanserin is a postsynaptic 5-HT1A agonist and 5-HT2A antagonist that modulates serotonin, dopamine, and norepinephrine activity in cortical and subcortical circuits tied to sexual desire. Unlike phosphodiesterase inhibitors used for arousal disorders, it acts centrally on neurotransmitter tone rather than on peripheral blood flow.

This mechanism explains why the monitoring schedule looks different from most reproductive-health drugs. Flibanserin undergoes extensive first-pass hepatic metabolism via CYP3A4 1. Any drug or substance that inhibits that enzyme pathway can multiply plasma concentrations of flibanserin by 2- to 7-fold, triggering clinically significant hypotension and syncope 2. The FDA documented that co-administration of fluconazole 200 mg (a moderate CYP3A4 inhibitor) increased flibanserin AUC by approximately 7-fold in a pharmacokinetic study [2]. That single finding shaped almost every monitoring and prescribing safeguard that followed.

The bedtime dosing requirement also derives from mechanism. Peak plasma concentration occurs about 0.75 hours post-dose, and sedation plus blood pressure dips overlap with that window [2]. Taking the tablet at bedtime means the patient sleeps through the highest-risk interval for orthostatic events.

Baseline Labs Before Starting Addyi

A liver function panel is the single most important pre-treatment lab. Flibanserin is contraindicated in hepatic impairment of any severity because reduced CYP3A4 metabolism raises drug exposure to dangerous levels 2.

Order ALT, AST, total bilirubin, and albumin before writing the first prescription. The FDA label does not specify numeric cutoffs beyond "hepatic impairment," so apply standard clinical thresholds: ALT or AST greater than 3 times the upper limit of normal warrants withholding the drug until further hepatology workup 3. A complete blood count is not required by the label but is reasonable if the patient reports fatigue, given the overlap between HSDD symptoms and anemia.

Record orthostatic blood pressure and heart rate at baseline. Measure supine readings, then repeat after two minutes of standing. The Addyi REMS program instructs prescribers to evaluate patients for conditions that predispose to hypotension, including dehydration, autonomic neuropathy, and concurrent antihypertensive use 4.

Complete a thorough medication reconciliation. Flag any moderate or strong CYP3A4 inhibitor on the patient's list. Common culprits include fluconazole, ketoconazole, erythromycin, clarithromycin, diltiazem, verapamil, and several HIV protease inhibitors [2]. Even grapefruit juice in large quantities can act as a moderate inhibitor. If a CYP3A4 inhibitor cannot be stopped, flibanserin is contraindicated.

The Addyi REMS Program: What Prescribers Must Complete

The FDA approved flibanserin in August 2015 with a Risk Evaluation and Mitigation Strategy (REMS) specifically because of the syncope and hypotension signal seen in alcohol-interaction studies 4. In 2019, the FDA modified the REMS to remove the original requirement that patients abstain from alcohol entirely, replacing it with a revised warning. The original alcohol-interaction study in 25 subjects found that 4 of 23 subjects (17%) who combined a single dose of flibanserin with 0.4 g/kg ethanol required clinical intervention for hypotension or syncope [2].

Prescriber certification requires completing an online training module and passing an assessment demonstrating competence in three areas: the interaction profile with CYP3A4 inhibitors, the alcohol-interaction risk, and the contraindication in hepatic impairment. Pharmacies must also be certified. Patients receive a counseling document before each dispense.

Dr. Sheryl Kingsberg, a clinical psychologist and researcher involved in multiple flibanserin trials, noted in a 2017 review: "The REMS was designed to ensure that prescribers understand the specific drug-interaction risks, which are the primary safety concern rather than the drug's intrinsic pharmacologic effects" 5.

Week-by-Week Follow-Up Timeline

The recommended monitoring cadence after starting flibanserin is straightforward because the drug does not cause organ toxicity requiring serial labs. Here is the practical timeline:

Week 1 to 2: Phone or portal check-in. Ask about sedation, dizziness on waking, and any episodes of lightheadedness. These are the most common adverse effects. In the BEGONIA trial (N=1,087), somnolence occurred in 11.4% of flibanserin-treated women vs. 3.3% on placebo, and dizziness in 9.4% vs. 1.8% 6. Most sedation events peaked in the first two weeks and attenuated with continued use.

Week 4: Optional visit or telehealth encounter. Reassess tolerability. Confirm ongoing alcohol avoidance (or limited use per 2019 revised labeling). Check whether any new medications have been started, particularly antibiotics or antifungals that inhibit CYP3A4.

Week 8: Efficacy reassessment (required). The FDA label states: "Discontinue flibanserin after 8 weeks if the patient does not report an improvement in sexual desire and associated distress" 2. Use a validated patient-reported outcome measure such as the Female Sexual Function Index (FSFI) desire domain or the Female Sexual Distress Scale-Revised (FSDS-R). Repeat orthostatic vitals at this visit. No repeat liver panel is needed unless clinical suspicion of hepatic injury has arisen.

Every 6 months thereafter. A medication reconciliation and brief symptom check is sufficient. Repeat the FSFI desire domain or FSDS-R annually to document continued benefit. No routine blood draws are required for patients with normal baseline hepatic function and a stable medication list.

Liver Function Monitoring: When to Recheck

Routine serial liver panels are not mandated by the FDA label for patients who had normal baseline values and no hepatic risk factors 2. Flibanserin itself has not been associated with drug-induced liver injury (DILI) in clinical trials or post-marketing surveillance at a clinically significant rate.

Recheck ALT and AST if:

• The patient develops new right upper quadrant pain, jaundice, or unexplained fatigue.
• A new medication with hepatotoxic potential is introduced (e.g., statins at high doses, valproic acid, certain antifungals).
• The patient begins consuming alcohol regularly, which independently raises the hepatic burden and worsens the flibanserin interaction risk.
• Weight gain or imaging suggests new non-alcoholic fatty liver disease.

Dr. James Simon, a clinical professor of OB/GYN at George Washington University and investigator in the VIOLET trial, stated: "Post-marketing data have not revealed a hepatotoxicity signal for flibanserin itself; the liver function testing requirement is a gatekeeper to identify patients whose impaired metabolism would lead to supratherapeutic drug levels" 7.

Blood Pressure and Orthostatic Monitoring

Hypotension is the primary physical safety concern. In pooled Phase III data, syncope occurred in 0.2% of flibanserin-treated patients taking the drug at bedtime without alcohol, compared with 0.1% on placebo 2. That gap widens substantially when CYP3A4 inhibitors or alcohol enter the picture.

Measure supine and standing blood pressure at baseline and at the 8-week follow-up. For patients on antihypertensive therapy, consider an additional check at week 2, because additive blood pressure lowering may unmask orthostatic symptoms that were subclinical before flibanserin was added 3.

Patients should be instructed to rise slowly from bed, especially during the first month. If a patient reports near-syncope or frank syncope at any time, hold flibanserin and evaluate before restarting. A tilt-table test is not routine but may clarify borderline cases in patients with underlying dysautonomia.

Drug Interaction Surveillance: The Ongoing Monitoring Priority

Medication reconciliation at every clinical touchpoint is the single most protective monitoring action for patients taking flibanserin. The risk matrix is binary: if a moderate or strong CYP3A4 inhibitor is co-prescribed, flibanserin must be stopped 2.

Common clinical scenarios where new CYP3A4 inhibitors appear mid-treatment include:

• A course of fluconazole for vaginal candidiasis. Even a single 150 mg dose raises concern, though the interaction magnitude depends on duration.
• Clarithromycin or erythromycin prescribed for respiratory infections. Azithromycin is not a significant CYP3A4 inhibitor and does not require flibanserin discontinuation.
• Initiation of diltiazem or verapamil for new-onset hypertension or rate control. Amlodipine and dihydropyridine calcium channel blockers are weak or negligible CYP3A4 inhibitors and are generally safer alternatives.
• Grapefruit juice consumption exceeding one glass daily.

Weak CYP3A4 inhibitors (e.g., cimetidine, oral contraceptives containing ethinyl estradiol) do increase flibanserin AUC modestly but are not contraindicated [2]. For these agents, counsel the patient to monitor for increased sedation and dizziness and consider a brief hold during the overlap if symptoms emerge.

CYP3A4 inducers (e.g., carbamazepine, phenytoin, rifampin, St. John's Wort) reduce flibanserin efficacy and are listed as a precaution rather than a contraindication [2]. If a strong inducer is started, expect diminished benefit and discuss whether continuing flibanserin is worthwhile.

Efficacy Benchmarks: What the Trials Actually Showed

Set patient expectations early. Flibanserin produces a modest, statistically significant improvement in desire, but the effect sizes are small. This matters for monitoring because patients who expect dramatic results may abandon therapy prematurely, while those with realistic expectations can evaluate genuine change at the 8-week mark.

In BEGONIA (N=1,087), flibanserin 100 mg at bedtime increased the mean number of satisfying sexual events (SSEs) by 0.8 per month over placebo at 24 weeks 6. The FSDS-R desire item improved by approximately 5.3 points in the flibanserin group vs. 3.6 on placebo (P<0.05) [6]. In the VIOLET trial (N=1,584), similar effect sizes were observed with a difference of 0.7 SSEs per month over placebo 8.

A pooled analysis of the three key trials (BEGONIA, VIOLET, DAISY; combined N=2,462 on flibanserin) found that 46.1% of flibanserin-treated patients achieved a clinically meaningful improvement on the FSDS-R desire domain vs. 34.1% on placebo, yielding a number needed to treat (NNT) of approximately 8 9.

At the 8-week reassessment, use these benchmarks: an increase of at least 1 SSE per month, a reduction in FSDS-R desire distress score by 3 or more points, or a patient-reported subjective improvement in sexual desire that she considers meaningful. If none of these criteria is met, the label recommends discontinuation.

Special Populations Requiring Modified Monitoring

Patients on SSRIs or SNRIs. Flibanserin was studied in women whose HSDD was not attributable to medication side effects, so using it to counteract SSRI-induced low desire is off-label. If a prescriber chooses this approach, monitor for additive CNS depression (sedation, cognitive slowing) with extra vigilance in the first four weeks. No specific lab modifications are needed, but a week-2 in-person or telehealth check is advisable 3.

Patients with well-controlled diabetes. Diabetic autonomic neuropathy increases baseline orthostatic hypotension risk. Check orthostatic vitals at baseline, week 2, and week 8 rather than just baseline and week 8.

Patients over 40 approaching perimenopause. Flibanserin is only FDA-approved for premenopausal women. If menopausal status is uncertain, check FSH and estradiol at baseline. A confirmed postmenopausal FSH level (typically >25 to 30 mIU/mL on two occasions) means the patient falls outside the approved indication.

Patients with BMI over 35. Flibanserin pharmacokinetics were not significantly altered by body weight in population PK analyses [2], but higher-BMI patients have increased prevalence of fatty liver disease. A liver ultrasound or FIB-4 calculation at baseline is prudent if hepatic steatosis is suspected.

Discontinuation Protocol

Flibanserin does not cause physical dependence, and no taper is needed. Stop it at bedtime and no withdrawal symptoms are expected 2. No post-discontinuation labs are required.

If discontinuing because of inadequate efficacy at 8 weeks, document the FSDS-R score and SSE count for the medical record. This documentation supports future therapeutic decisions if the patient considers re-trial or alternative agents such as bremelanotide (Vyleesi), which operates through a different mechanism (melanocortin-4 receptor agonism) and does not require hepatic monitoring 10.

Patients who had benefit and wish to stop should be counseled that HSDD symptoms typically return to baseline within one to two menstrual cycles after discontinuation, based on open-label extension data showing no sustained post-treatment carry-over effect 9.